SecBot SecBot
PRESS-RELEASE ·Filed Nov 3, 2026

TARS

Tarsus Pharmaceuticals, Inc
NEUTRAL
Impact 5/10
Horizonimmediate Processed13d 10h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Focus on XDEMVY's continued prescription growth trajectory and refill rate, which signal durable demand. The large IPR&D charges are one-time and non-cash; watch for pipeline catalysts in H1 2027 (TP-04 Phase 2, TP-05 Phase 2 results) and the Phase 3 start for IRX-101.

DirectionNeutral
Confidencehigh
Horizonimmediate

ALK-001

● Neutral Named in this press release
Impact
Phase
Phase 3
Time to market
If the Phase 3 NORTHSTAR trial succeeds, potential FDA approval would likely follow in 2030 or later, given topline data is not expected until H2 2029.
Next catalyst
None dated

What to watchALK-001 has no near-term binary catalyst, the Phase 3 NORTHSTAR topline readout is not expected until H2 2029. TARS stock will be driven primarily by XDEMVY commercial execution and nearer-term pipeline catalysts (TP-04, TP-05) over the next 12 months. Monitor the Alkeus acquisition close and any early NORTHSTAR enrollment updates, but do not trade TARS on ALK-001 expectations alone.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$69.07
T+0 close · Nov 3, 2026 · via day close
Latest settled
+11.13%
T+5 · $76.76 · next T+20 in 16d
Vs SPY
+12.05%
α at T+5
Latest observation
+16.93%
T+7 · FF3 residual α
  1. T+0 · Nov 4 $69.07entry
  2. T+1 · 12d ago −2.24%α +2.17% · $67.52
  3. T+5 · 6d ago +11.13%α +12.05% · $76.76
  4. T+8 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Tarsus reported Q3 2026 XDEMVY net product sales of $194.6M, up ~64% YoY and above the $190.8M consensus. However, the GAAP net loss widened to $668.3M ($14.40 per share) vs the $-1.77 consensus estimate, driven by $632.2M in acquired IPR&D expenses from the iRenix and Alkeus acquisitions. The underlying commercial momentum is strong, but the large one-time charges make headline earnings uninformative.

Key Financial Metrics

EPS
−$14.40
Revenue
$194.6M
est $190.8M · +2.0% · +63.9% YoY
Gross Margin
93%

Key Facts

  • XDEMVY net product sales $194.6M in Q3 2026, up ~64% YoY from $118.7M
  • Revenue of $194.6M beat consensus of $190.8M
  • GAAP net loss per share $(14.40) vs consensus $(1.77), driven by $632.2M in acquired IPR&D expenses
  • Gross margin remained consistent at ~93%
  • Cash, cash equivalents and marketable securities $309.6M as of Sep 30, 2026
  • Surpassed 1M bottles dispensed and $1B cumulative net product sales since launch
  • Refills accounted for ~20% of XDEMVY prescriptions in Q3
  • Appointed Neera Clase as Chief Commercial Officer
  • Completed acquisitions of iRenix Medical (IRX-101) and Alkeus Pharmaceuticals (gildeuretinol)

Financial Impact

Revenue beat consensus by ~$3.8M (2.0%); GAAP EPS miss of $(14.40) vs $(1.77) due to $632.2M non-cash IPR&D charge

revenueepsnet loss

Risk Factors

  • GAAP net loss of $668.3M in Q3 alone, though largely driven by non-cash acquisition accounting
  • R&D and SG&A expenses rising sharply (R&D $44.2M vs $16.3M, SG&A $168.0M vs $108.6M YoY)
  • Pipeline programs (TP-04, TP-05, IRX-101, gildeuretinol) are early-stage with no near-term revenue

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3394778

Track record

21 reports on TARS

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +27.36% at T+20 after the Aug 6, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago 144 Neutral 2/10 Entry $76.56 Now $78.68 +2.78% settles Nov 23
  2. Nov 5, 202611d ago 3 Neutral 2/10 Entry $68.60 to $80.28 Now $78.68 +14.69% ▲ +17.03% +14.43% vs SPY
  3. Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $67.52 to $76.89 Now $78.68 +16.53% ▲ +13.88% +10.59% vs SPY
  4. Nov 3, 202613d ago 8-K Neutral 5/10 No price data
  5. Nov 3, 202613d ago Press Release Neutral 5/10 Viewing Entry $69.07 to $76.76 Now $78.68 +13.91% ▲ +11.13% +12.05% vs SPY
  6. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $69.50 to $70.03 Now $78.68 +13.21% ▲ +0.76% +0.91% vs SPY
  7. Oct 13, 20264w ago S-3ASR Neutral 4/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  8. Oct 13, 20264w ago S-3ASR Neutral 3/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $81.12 to $79.03 Now $78.68 −3.01% ▼ −2.58% −3.21% vs SPY
  10. Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $90.78 to $79.95 Now $78.68 −13.33% ▼ −11.93% −10.72% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026